Kristin M Berg1,2,3, Douglas E Jorenby2, Timothy B Baker2, Michael C Fiore2. 1. Division of General Internal Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, 2828 Marshall Ct, Suite 100, Madison, WI USA 53705. 2. Center for Tobacco Research and Intervention, University of Wisconsin School of Medicine and Public Health, 1930 Monroe St, Suite 200, Madison, WI USA 53711. 3. Primary Care Research Fellowship, Department of Family Medicine and Community Health, University of Wisconsin School of Medicine and Public Health, 1100 Delaplaine Ct, Madison, WI USA 53715.
Abstract
INTRODUCTION: The majority of attempts to stop smoking end in failure. One way to improve success may be to explore different combinations of existing cessation medications. AIMS: This observational study examined "triple therapy" (varenicline + nicotine patch + nicotine lozenge) in 36 smokers trying to quit. METHODS: A 12-week, observational study exploring tolerability, via adverse events (AEs) elicited at each of 9 phone assessments. Secondary outcomes included satisfaction rates, medication changes, and self-reported quit rates at week 12. RESULTS: 35 of 36 participants reported at least one AE. Insomnia (75%), abnormal dreams (72%) and nausea (64%) were most common. Most were mild to moderate. No deaths, hospitalizations, cardiovascular events, or suicidality were reported. Six participants (17%) decreased the dose of at least one medication, 5 (14%) decreased the dose then discontinued at least one medication, and 13 (36%) discontinued at least one medication without trying a lesser dose. Participants were highly satisfied with their medications, and 58% reported quitting at 12 weeks, with 38% reporting prolonged abstinence. CONCLUSION: Despite high rates of AEs and medication changes, high rates of satisfaction and self-reported quitting, with no serious AEs, were observed with triple therapy. Additional data on tolerability and efficacy are needed. TRIAL REGISTRATION: clinicaltrials.gov number NCT02681510.
INTRODUCTION: The majority of attempts to stop smoking end in failure. One way to improve success may be to explore different combinations of existing cessation medications. AIMS: This observational study examined "triple therapy" (varenicline + nicotine patch + nicotine lozenge) in 36 smokers trying to quit. METHODS: A 12-week, observational study exploring tolerability, via adverse events (AEs) elicited at each of 9 phone assessments. Secondary outcomes included satisfaction rates, medication changes, and self-reported quit rates at week 12. RESULTS: 35 of 36 participants reported at least one AE. Insomnia (75%), abnormal dreams (72%) and nausea (64%) were most common. Most were mild to moderate. No deaths, hospitalizations, cardiovascular events, or suicidality were reported. Six participants (17%) decreased the dose of at least one medication, 5 (14%) decreased the dose then discontinued at least one medication, and 13 (36%) discontinued at least one medication without trying a lesser dose. Participants were highly satisfied with their medications, and 58% reported quitting at 12 weeks, with 38% reporting prolonged abstinence. CONCLUSION: Despite high rates of AEs and medication changes, high rates of satisfaction and self-reported quitting, with no serious AEs, were observed with triple therapy. Additional data on tolerability and efficacy are needed. TRIAL REGISTRATION: clinicaltrials.gov number NCT02681510.
Authors: Megan E Piper; Thomas M Piasecki; E Belle Federman; Daniel M Bolt; Stevens S Smith; Michael C Fiore; Timothy B Baker Journal: J Consult Clin Psychol Date: 2004-04
Authors: Coenraad F N Koegelenberg; Firdows Noor; Eric D Bateman; Richard N van Zyl-Smit; Axel Bruning; John A O'Brien; Clifford Smith; Mohamed S Abdool-Gaffar; Shaunagh Emanuel; Tonya M Esterhuizen; Elvis M Irusen Journal: JAMA Date: 2014-07 Impact factor: 56.272
Authors: Robert M Anthenelli; Neal L Benowitz; Robert West; Lisa St Aubin; Thomas McRae; David Lawrence; John Ascher; Cristina Russ; Alok Krishen; A Eden Evins Journal: Lancet Date: 2016-04-22 Impact factor: 79.321